Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s ...
The goal of this collaborative was to examine the contributing factors towards the failure of late-stage clinical product development and develop key considerations for stakeholders to improve the ...
Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to new research ...
Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
Parkinson drug development halted as Biogen and Denali stop BIIB122 after phase 2b trial failed to slow disease progression.
Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said ...
Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results